Use: This test should be considered for the differential evaluation of patients who present with rapidly progressive dementia of undetermined etiology, especially with cognitive impairment and neuronal degeneration.

Limitations: This test was developed and its performance characteristics determined by Labcorp in accordance with CLIA requirements. This test has not been cleared or approved by the Food and Drug Administration.

Methodology; Immunofluorescence, EIA, Immunoblot